PRIA Logo™
117-hr-7640117th Congress

To amend the Orphan Drug Act to reauthorize a program of grants and contracts for the development of drugs for rare diseases and conditions (commonly referred to as "orphan drugs").

Sponsored By: Representative Bilirakis, Gus M. [R-FL-12]

Unknown

Summary

This bill reauthorizes through FY2027 the Food and Drug Administration's Orphan Products Grants Program, which supports clinical research and product development for rare diseases and conditions.

Personalized for You

How does this bill affect your finances?

Personalize government policy and PRIA will tell you what this bill means for your household, plus every other piece of legislation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.

Free to download

Bill Overview

No Economic Impacts Identified for this Bill

Sponsors & CoSponsors

Sponsor

Bilirakis, Gus M. [R-FL-12]

FL • R

Cosponsors

  • Rep. Butterfield, G. K. [D-NC-1]

    NC • D

    Sponsored 5/3/2022

Roll Call Votes

No roll call votes available for this bill.

View on Congress.gov
Back to Legislation